Top Markets
#1 QuantixAI QuantixAI +105.36%
#2 龙虾 (Lobster) 龙虾 (Lobster) +62.18%
#3 MetaDAO MetaDAO +28.24%
#4 Pons Pons +27.98%
#5 Rain Rain +23.16%
#6 Bedrock Bedrock +20.46%
#7 Ontology Gas Ontology Gas +18.79%
#8 Prom Prom +14.96%
#9 Humanity Humanity +14.75%
#10 DOG•GO•TO•THE•MOON (Runes) DOG•GO•TO•THE•MOON (Runes) +13.68%
Coin of the day
QuantixAI QuantixAI
सेटिंग्स
भाषा
हिन्दी
मुद्रा
USD
थीम
Heidelberg Pharma AG Heidelberg Pharma AG

Heidelberg Pharma AG

HPHA
शेयरों में रैंक #20137
Heidelberg Pharma AG is a biopharmaceutical firm dedicated to oncology, with a... Heidelberg Pharma AG is a biopharmaceutical firm dedicated to oncology, with a specific emphasis on its innovative antibody-targeted amanitin conjugates (ATAC) technology. The company conducts its activities across Germany, various other European countries, the United States, and globally. Its primary drug candidate, HDP-101, is presently in Phase I/IIa clinical trials for individuals suffering from relapsed or refractory multiple myeloma. The pipeline also features several other ATAC compounds: HDP-102 is being developed for non-Hodgkin lymphoma; HDP-103 targets metastatic castration-resistant prostate cancer; HDP-104 is aimed at various tumor types; and HDP-XX addresses both solid and hematological tumors. Further development programs include MGTA-ATACs, designed for hematopoietic stem cells (HSCs) and conditioning treatments for blood cancers and genetic conditions, alongside TAK-ATACs for broader oncology use. Heidelberg Pharma's offerings extend to diagnostic and therapeutic antibodies. TLX250-CDx, a diagnostic antibody for imaging purposes, is in Phase III for renal cancer, Phase I for urothelial carcinoma (bladder cancer), and Phase II for triple-negative breast cancer. Additionally, TLX250 (girentuximab), a therapeutic antibody, is undergoing Phase II evaluation for patients with advanced clear cell renal cell carcinoma. The company's diverse portfolio is complemented by RHB-107, an oral serine protease inhibitor in Phase II/III studies for both COVID-19 and advanced cholangiocarcinoma, as well as LH011 for pancreatic cancer. A significant licensing agreement and strategic partnership with Huadong Medicine Co., Ltd. grants the latter development and commercialization rights for HDP-101 and HDP-103 throughout Asia. Established in Ladenburg, Germany, in 1997, the company was formerly known as Wilex AG before rebranding to Heidelberg Pharma AG in October 2017.
शेयर मूल्य
$2.99
मार्केट कैप
$139.84M
बदलाव (1 दिन)
-0.40%
बदलाव (1 वर्ष)
-41.27%
देश
DE
व्यापार Heidelberg Pharma AG (HPHA)

श्रेणी

Healthcare
Heidelberg Pharma AG (HPHA) के लिए स्टॉक मूल्य इतिहास
दिन का सबसे उच्च समापन मूल्य: $2.99 (2026-08-01 को)

दिन का सबसे निम्न समापन मूल्य: $68.95 (2006-11-01 को)
Heidelberg Pharma AG के स्टॉक मूल्य का इतिहास 2006 से 2026 तक
प्रत्येक वर्ष के अंत में स्टॉक मूल्य प्रदर्शन
वर्ष प्रदर्शन
2026 (TTM) 8.96%
2025 24.78%
2024 -34.62%
2023 -35.99%
2022 6.20%
2021 -25.03%
2020 214.32%
2019 -21.18%
2018 -12.11%
2017 65.41%
2016 10.32%
2015 -15.82%
2014 -69.90%
2013 54.37%
2012 -75.41%
2011 -18.87%
2010 8.30%
2009 41.38%
2008 -53.24%
2007 -52.21%
2006 0.00%
समान कंपनियों या प्रतिस्पर्धियों के स्टॉक मूल्य
कंपनी स्टॉक मूल्य परिवर्तन 1व% देश
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $553.09 42.20%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $1.02K 50.56%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $158.64 525.80%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $122.47 -12.71%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $772.27 8.67%
CH